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INDUCTION OF PLURIPOTENCY IN HUMAN KERATINOCYTES THROUGH 
mRNA TRANSFECTION.  Robert D. Leone, Peter M. Rabinovich, Eugenie Cheng, 
Efim Golub, and Sherman M. Weissman. Department of Genetics, Yale University, 
School of Medicine, New Haven, CT.  
Induced pluripotent stem (iPS) cells are epigenetically reprogrammed somatic cells that 
exhibit developmental and proliferative characteristics of embryonic stem (ES) cells. 
Other than alterations made during the reprogramming process, iPS cells are 
genotypically identical to donor tissue, giving them significant potential in regenerative 
medicine, basic biology of genetic disease, and drug development. Presently, iPS cell 
derivation largely relies on the introduction of reprogramming factors (eg, OCT4, SOX2, 
KLF4, c-MYC) directly into cellular genomes, leaving cells vulnerable to insertional 
mutagenesis and persistent expression of oncogenic transcription factors. This severely 
limits their use in clinical and research settings. Here we describe the reprogramming of 
human keratinocytes through the introduction of exogenous mRNA transcripts.  mRNA 
presence within cells is transient and is unlikely to have permanent effects on the cellular 
genome, thus avoiding the pitfalls of present methods of iPS cell generation. Several 
benchmarks have been achieved toward this end, includ-ing: 1) successful expression in 
human cells of reprogramming factor proteins through the introduction of exogenous 
mRNA transcripts; 2) phenotypic transformation of human keratinocytes toward ES cell 
morphology by transfection with mRNA reprogramming factors; and 3) alkaline 
phosphatase activity (a well described early marker of pluripotency) in a small proportion 
of transformed cells. These results imply that mRNA transfection may be a viable method 
for reprogramming somatic cells towards pluripotency.
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BACKGROUND 
Human embryonic stem (hES) cells are characterized by two fundamental qualities: the 
ability to indefinitely self-renew, and the capacity to differentiate into any and all tissues 
of the body. Since first being isolated in 1998, hES cells have been the subject of 
significant attention from researchers as well as the lay public (1). Potential applications 
of these pluripotent and inexhaustible cells include studies of basic mechanisms of 
disease, screens for drug discovery, and the possibility of generating tissue for use in 
patients with degenerative diseases such as Parkinson disease, patients in need of bone 
marrow transplantation, or patients with infarcted cardiac tissue (2,3,4,5). One limitation 
of ES cells, however, is that they are generic in nature, and as such are unrelated to 
patients who may be the beneficiaries of such use. Consequently, tissues derived from 
hES cell lines will likely be the target of immune rejection in recipients (6,7). Also, 
because the only known source of hES cells is the inner cell mass of a human blastocyst, 
research into the basic nature and potential application of hES cells has been embroiled in 
ethical, religious, and political concerns. Spurred on by both the promise, as well as the 
limitations of hES cells, researchers have investigated alternative means of achieving 
pluripotency. These investigations have taken the form of nuclear transfer experiments 
(8,9), cell fusion experiments between somatic cells and ES cells (10,11), and the design 
of transformative cell culture conditions to attain pluripotency in testis cells (12,13).  
 
Somatic cell nuclear transfer (SCNT), wherein a somatic cell nucleus is transplanted into 
an oocyte or ES cell and subsequently achieves pluripotency through epigenetic 
reprogramming, has been successfully demonstrated in a variety of non-human, 
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mammalian species (most notably in “Dolly” the sheep in 1996) (9,14,15).  The products 
of successful SCNT experiments are pluripotent cells that are identical in genomic 
makeup to the starting cell nucleus (14). While this approach would theoretically produce 
patient-specific, rejection-proof pluripotent cells for therapeutic and analytical use, it is 
limited by several challenges. SCNT technology requires the use of unfertilized oocytes, 
which are difficult to obtain. Though it is possible that this limitation may be overcome 
by the use of fertilized zygote cells, as was recently shown in the mouse, SCNT is also a 
very technically challenging and inefficient technology that is not at present viable for 
routine use in the clinic (16). 
 
Despite limitations, SCNT experiments have shown unequivocally that cellular 
differentiation is not necessarily a one-way street. By exposing a somatic nucleus to the 
appropriate cytocellular environment (oocyte or ES cell), epigenetic reprogramming is 
facilitated and pluripotency established. In the last several years, researchers have applied 
these concepts as they have attempted to more fully understand the specific elements 
present in oocytes and ES cells that affect nuclear reprogramming and maintain 
pluripotency. By carefully sifting through data examining transcription factors present in 
ES cells, researchers were able to identify a set of four such factors that were sufficient to 
reprogram somatic cells to pluripotency. In a biomedical milestone reported in 2006, 
Takahashi and Yamanaka successfully reprogrammed murine embryonic fibroblasts to 
de-differentiated states of pluripotency using retroviral insertion of gene sequences of 
four transcription factors: Oct4, Sox2, Klf2, c-Myc (7). These cells have been termed 
“induced pluripotent stem cells” (iPS cells). These results were extended to the 
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reprogramming of human fibroblast cells in the laboratory of James Thompson in 2007 
using retroviral insertion of gene sequences for OCT4, SOX2, NANOG, and LIN28 (17). 
In the last few years iPS cells have been derived by various researchers from several 
different human cell types including keratinocytes, hematopoietic cells, cord blood, and 
hair follicle cells (18, 19, 20, 21). 
 
Though the precise criteria for pluripotency is the subject of ongoing debate (22), iPS 
cells have been shown to be similar to embryonic cells in several important ways (23, 
24).  iPS cells show significant similarity to ES cells morphologically, epigenetically, and 
in their expression of key ES cell marker genes. iPS cells also demonstrate other 
important characteristics of pluripotency, including the ability to form teratomas when 
injected into mouse testes, the ability to contribute to tissues of adult chimeric mice that 
are germline competent, and the ability to form all tissues of a viable organism through 
tetraploid complementation assays (23, 24, 25). Though the most stringent of these 
assays—chimera formation and tetraploid complementation—are not ethically available 
for work involving human iPS cells, these cells have been successfully induced to form 
teratomas comprising three primary germ cell layers and have been subjected to several 
differentiation schemes to form specific human tissues, such as cardiomyocytes, 
hematopoietic stem cells, osteoclasts, hepatocytes, and neurons (18, 23, 24, 26, 27, 28, 
29). 
 
The ability to reprogram somatic cells to pluripotency has led to great excitement in the 
field of stem cell research and regenerative medicine. These reprogrammed somatic cells 
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have several important advantages over ES cells in biomedical application. First, iPS cell 
technology avoids ethico-religio-political complexities that have bridled embryonic stem 
cell research for much of the last decade. Second, iPS cells are derived in a patient-
specific manner, and so, organs and tissue derived from these cells are likely to avoid 
immune rejection that would otherwise complicate application in regenerative medicine. 
Third, the patient-specific nature of iPS cells allows for the observation of developmental 
irregularities that are likely inherent in many disease states. For example, iPS cells 
derived from individuals with Parkinsons Disease or ALS can be differentiated into 
dopaminergic neurons and monitored developmentally for insight into sequential 
pathologic aberrations inherent in the disease process (30, 31, 32). Lastly, this technology 
holds great promise for evaluating medication-induced abnormalities in a tissue-specific, 
patient-specific manner.  That is, although the nature of the toxicity of a particular drug 
on heart tissue may theoretically be ascertained by studies on cardiomyocytes derived 
from ES cells, the results could not take into account phenotypic and functional 
polymorphisms that may present in a given individual. iPS cell derivation could allow 
such tailored study (33).  
 
Despite the enormous promise of iPS cell technology, the field is presently limited in 
clinical application due to the manner of iPS cell derivation. Present methods of somatic 
cell reprogramming rely largely on viral vectors to introduce genetic material 
permanently into the genome. Inserted genetic material includes both the viral backbone, 
as well as transgene sequences coding for the transformative factors (OCT4, SOX2, 
KLF4, c-MYC, NANOG, LIN28) (7,17). Such an approach engenders several significant 
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pitfalls that at present limit clinical application. First, virally introduced material can 
produce insertional mutagenesis, disrupting the normal function of endogenous genetic 
material and leading to unintended phenotypes and possibly malignant transformation 
(34). Mutagenetic effects may also have significant effects on the differentiation potential 
of established iPS cells. Second, inserted transgenes may continue to be active after 
pluripotency has been established. This may also have implications for the differentiation 
potential of iPS cells, but, perhaps more importantly, has the potential to activate a 
tumorigenic phenotype, which is especially concerning considering the association of 
several of the induced factors (c-MYC, KLF4) with malignant transformation (17, 35).  
 
In order for the full promise and clinical viability of iPS technology to be realized, 
pluripotency must be achieved by means that minimize or eliminate unanticipated and 
undesired phenotypes such as malignant transformation. This problem has been 
approached by several researchers in a variety of ways, including using adenoviruses or 
episomal vectors to provide nonintegrating transfer of genetic material (36, 37), 
Cre/LoxP recombination and Piggy-Bac technology to remove inserted genetic material 
after cellular transformation has been achieved (38, 39, 40), and protein-based schemes 
have been reported. Unfortunately these approaches also have significant drawbacks that 
limit their usefulness in the clinical setting, including very low yield, long turn-around 
time, and complicated procedures. In addition, many of these approaches continue to rely 
on the introduction of exogenous DNA into host cells, failing to completely remove the 
possibility of genetic recombination at the level of the genome. Post-transformation 
excisional schemes using Cre/LoxP recombination has the additional limitation of 
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imprecise excision of integrated transgenes, thus failing to circumvent concerns of 
insertional mutagenesis. The use of DNA constucts, such as episomal material, for 
transient transfection is problematic because of the inherent toxicity of DNA which limits 
the concentration range that can be used effectively (41). DNA also requires nuclear entry 
which is limited in some cell types (41). Such methods can also lead to low-frequency 
integration into host genome (42). 
 
In an attempt to address many of the limitations of current procedures in deriving human 
iPS cells, we have investigated the viability of using mRNA transfection of somatic cells 
to induce pluripotency. The most important aspect of this approach lies in the fact that 
mRNA, unlike DNA, is unlikely to have a permanent effect on the cellular genome. 
mRNA is completely and irreversibly degraded, eventually leaving transfected cells 
absent of any transgene expression. Also, translation of mRNA into protein, unlike DNA-
based methods, does not require nuclear entry. Rabinovich et al. have recently developed 
a fast and effective approach for in vitro synthesis of mRNA that can be introduced into 
human cells (41). These studies showed that mRNA transfection of human cells can be 
achieved at efficiencies much higher than that of DNA transfection, with a more uniform 
introduction of material across cell populations. This approach has successfully been 
employed to reprogram different types of primary cells and cell lines, including T 
lymphocytes, NK cells, B cells, and several cancer cell lines. T lymphocytes, and natural 
killer cells have been reprogrammed with chimeric immune receptor (CIR) constructs 
that direct these cells towards various surface targets (43). For example, by using anti-
CD19 CIR and anti-8H9 CIR, a variety tissue types have been targeted by the 
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reprogrammed killer cells, including B cells, Daudi lymphoma, primary melanoma, 
breast ductal carcinoma, breast adenocarcinoma, and rhabdomyosarcoma (43). In the 
present study we have adapted these methods of mRNA transfection to develop an 
approach for the reprogramming of somatic cells to pluripotent states.  
 
Recently, many researchers have addressed the poor efficiency and slow kinetics of iPS 
cell generation. Various methods have been successful in this regard. First, the choice of 
starting cell type bears heavily on the speed and efficiency of the reprogramming process. 
Although fibroblasts have been the standard starting tissue for most iPS cell studies, 
several investigators have reported that keratinocytes reprogram faster and more 
efficiently in both mouse and human systems (18, 44). There have also been mouse 
studies showing that early progenitors and hematopoietic stem cells are more easily and 
more quickly reprogrammed than more well-differentiated hematopoietic cells (45).  
Second, small molecule epigenetic modifying factors, such as valproic acid (histone 
deacetylase inhibitor) and 5’-azacytidine (DNA-hypomethylating agent), have also been 
shown to enhance the success of reprogramming (46). It is thought that these agents aid 
in the chromatin remodeling that must occur to produce fully transformed cells. Valproic 
acid has been shown to increase efficiency of reprogramming up to 40 times and has 
allowed reprogramming with the use of only two exogenous factors, OCT4 and SOX2 
(46, 47). Third, recent studies have demonstrated that knock-down of P53 activity can 
enhance reprogramming. The process of reprogramming has been shown to activate the 
P53 pathway which in turn acts as a barrier to full reprogramming (48, 49). Lastly, the 
use of five factors (OCT4, SOX2, KLF4, c-MYC, NANOG) instead of the standard four 
  
13 
factors has shown promise in increasing yield and kinetics of iPS cell formation, 
especially in systems that do not employ retroviruses as the means of reprogramming (37, 
50). 
 
In the present work, we have optimized mRNA electroporation protocols for 
keratinocytes, performed in vitro mRNA synthesis of factors required for iPS 
reprogramming (OCT4, SOX2, KLF4, c-MYC, and NANOG) and demonstrated that, 
upon transfection, these transcripts produce detectable protein. In an effort to optimize 
the yield of transformed cells, we have also synthesized a truncated form of P53, known 
as P53DD, which has been shown to have a dominant negative effect on P53 activity in 
human cells (49, 51). We have investigated the capacity of both human keratinocytes and 
human fibroblasts to transform under various conditions, including 4 and 5 factor mRNA 
transfection, in the presence of valproic acid, and with concomitant transfection with a 
P53 dominant negative construct.  The presence of iPS cell generation has been assessed 
by the presence of alkaline phosphatase activity of formed colonies, which is well known 
as an early marker of pluripotency.  We have observed the generation of a small number 
of alkaline phosphatase-positive cells by electroporating human keratinocytes with 
OCT4, SOX2, KLF4, c-MYC, and NANOG. 
 
  
14 
MATERIALS AND METHOD 
Cell Culture. Neonatal human epidermal keratinocytes (nHEK) and nenotal human 
foreskin fibroblasts (nHFF) were obtained from the Yale Cell Culture Core Facility. 
Keratinocytes were cultured in serum-free low calcium medium (Epilife, Invitrogen); 
fibroblasts were cultured in DMEM medium in 10% heat-inactivated fetal bovine serum 
(Gibco). For viral reprogramming, keratinocytes, passage 5-6, were infected with a 
1:1:1:1 mix of retroviruses with OCT4, SOX2, KLF4, and c-MYC in the presence of 
1µg/ml polybrene and centrifuged for 45 minutes at 750g on 2 consecutive days. For 
reprogramming with mRNA constructs, keratinocytes were electroporated with mRNA 
transcripts corresponding to reprogramming factors as described below. For initial 
experiments mRNA corresponding to each of four transcription factors (OCT4, SOX2, 
KLF4, c-MYC) were used in a 1:1:1:1 ratio respectively. For experiments using high 
OCT4 concentrations, the same four factors were used in a 3:1:1:1 ratio. For experiments 
using the initial four factors plus either NANOG or P53DD, the five mRNA transcripts 
were present in a ratio of 1:1:1:1:1.  After viral infection or electroporation, keratinocytes 
were grown in fresh serum-free, low calcium medium at 37C and 5% CO2 for 2 days, 
after which they were trypsinized and seeded onto multi-well plates containing irradiated 
mouse fibroblasts. Transfected cells were seeded 2.5 x 106 cells/cm2 and cultured with ES 
cell medium (DMEM/F12 containing 20% KOSR (vol/vol), 5–10 ng ml- 1 bFGF, 1 mM 
L-GIn, 100 M nonessential amino acids, 100 M 2-mercaptoethanol, 50 U ml- 1 
penicillin and 50 mg ml- 1 streptomycin).  Neonatal human foreskin fibroblasts were used 
to confirm the expression of individual mRNA constructs of the various reprogramming 
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factors and were cultured in DMEM with 10% heat inactivated fetal bovine serum.  All 
cell culture procedures were carried out by Robert Leone. 
 
Retroviral production. Following the method of Park, et al., retroviruses containing 
OCT4, SOX2, KLF4, and c-MYC were formed using pMIG vectors (Addgene) which 
also contained sequence for GFP expression (52).  The production of retroviruses was 
carried out by Eugenie Cheng in the laboratory of Haifan Lin. 
 
RNA synthesis.  As described in Rabinovich et al. (41, 43), green fluorescent (GFP) 
mRNA constructs were produced in vitro with T7 polymerase and were based on the 
Pontellina plumata GFP sequence of plasmid pmaxGFP (Amaxa Biosystems, Cologne, 
Germany) (41,43). OCT4, SOX2, KLF4, c-MYC, P53DD, and NANOG constructs were 
created by replacing the GFP coding region in pmaxGFP with the appropriate open 
reading frame from each gene. DNA templates were produced by polymerase chain 
reaction (PCR) using AccuPrime Pfx DNA polymerase (Invitrogen) according to 
manufacturer’s protocol. Twenty-five to 30 cycles of PCR were performed in a standard 
50-µl reaction using 0.1 mg of template DNA. The forward primer contained the T7 
RNA promoter and an anchoring sequence in the proximal part of the gene expression 
cassette. The reverse primer, with anchoring sequence in the distal part of the gene 
expression cassette, contained a stretch of 100 dT residues. Design of DNA inserts for 
OCT4, KLF4, SOX2, c-MYC, and NANOG was carried out Peter Rabinovich. Design of 
the DNA insert sequence for the P53 dominant negative construct (P53DD) was carried 
out by Robert Leone. PCR was carried out by Efim Golub. 
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mRNA synthesis with T7 RNA polymerase has been described by Rabinovich et al. (41, 
43). This was performed with an mMESSAGE mMACHINE T7 Ultra kit (Ambion, 
Austin, TX), using the procedure recommended by the manufacturer. One hundred to 200 
ng of DNA made by PCR with no further purification was used for the standard 20-µl 
transcription reaction. The product was treated with Escherichia coli poly(A) polymerase 
(from the same kit) in the presence of 1mM ATP according to the Ambion 
polyadenylation protocol. The yield of mRNA was 20 to 60 mg of mRNA per reaction. 
The final product was treated with DNase I (Ambion) and purified by LiCl precipitation. 
RNA was stored at -80C.   mRNA production was performed by Robert Leone.  
 
mRNA transfection of human cells 
Electroporation of human keratinocytes and fibroblasts. 
Electroporation was performed with an Amaxa Nucleofector II (Amaxa, Gaithersburg, 
MD) in accordance with manufacturer recommendations. Keratinocytes were 
electroporated with ‘‘Human Keratinocyte Nucleofector Kit Solution’’ and programs 
T007, T018, and T024. Human fibroblasts were electroporated with ‘‘Human Dermal 
Fibroblast Nucleofector Kit Solution’’ using program U020. For GFP transfection 
experiments, keratinocytes were electroporated with DNA (20µg/ml) or mRNA (30-
200µg/ml) per sample. Cells were used at a concentration of 10–250 million/ml. In this 
interval of values the efficiency of transfection does not depend on cell density 
(Rabinovich et al., 2006). The efficiency of transfection was determined by flow 
cytometry 18 hours after transfection.  Cell viability post-transfection was assessed by 
tryptan blue staining hemocytometry. In standard reprogramming experiments, OCT4, 
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SOX2, KLF4, and c-MYC were used in a 1:1:1:1 ratio with 30µg/ml final concentration 
of each factor. In experiments containing high OCT4, a 3:1:1:1 ratio was used. In 
experiments using NANOG, a 1:1:1:1:1 ratio (OCT4:SOX2:KLF4:c-MYC:NANOG) was 
used. In experiments using P53DD (P53 dominant negative construct), a 1:1:1:1:1 ratio 
(OCT4:SOX2:KLF4:c-MYC:P53DD) was used.  All electroporation procedures reported 
on in this work was performed by Robert Leone. 
 
Cationic liposomal transfection of human keratinocytes and fibroblasts. 
Cationic-liposomal transfection experiments were carried out using the TransIT®-mRNA 
Transfection Kit (Mirus).  Conditions were optimized for keratinocyte and fibroblast 
transfection according to the manufacturer’s recommendations using both GFP plasmid 
as well as GFP mRNA transcripts produced by the above methods.  Transfection of both 
keratinocytes and fibroblasts was performed in cell culture conditions on a feeder layer of 
irradiated mouse embryonic fibroblasts as described above. Optimization of transfection 
conditions for keratinocytes was performed by Robert Leone. Optimization of 
transfection conditions for fibroblasts was performed by Eugenie Cheng. Mirus 
transfection experiments using reprogramming factors was carried out by Eugenie Cheng. 
 
Flow Cytometry. Flow cytometric analysis of cell subpopulations was performed at the 
Yale Cancer Center Flow Cytometry Shared Resource (New Haven, CT), using a 
FACSCalibur (BD Biosciences). Fluorescence signals were collected using a 488-nm 
laser on a logarithmic scale. Unless otherwise noted, at least 10,000 events were acquired 
for each sample. Data were analyzed with FlowJo software (TreeStar, Ashland, OR).  
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Flow cytometric analysis was carried out by Robert Leone with assistance from Eugenie 
Cheng and Peter Rabinovich. 
 
Electrophoresis. All protein expression assays were performed on cell lysates from 
transfected neonatal human foreskin fibroblasts, passage 7-12. In the presence of protease 
inhibitors, whole cell extracts were obtained by lysis using either RIPA buffer and 
standardized against untransfected control cells using BCA protein quantitation (c-MYC, 
NANOG, P53DD) or laemmli buffer and standardized against untransfected controls by 
cell concentration measurement (KLF4, SOX2, OCT4). Protein extracts were analyzed 
by Western blot analysis using specific antibodies against c-MYC (StemGent 09-0032 at 
1:100 dilution); NANOG (Abcam ab80892 at 1:100 dilution); P53 (Calbiochem Pab421 
at 1:10 dilution), KLF4, SOX2, OCT4. Alkaline phosphatase-conjugated goat anti-mouse 
antibody (sc-2005, Santa Cruz) and goat anti-rabbit antibody (sc-2004, Santa Cruz) were 
used as secondary antibodies at 1/500-1/2000 dilution range. Blots were developed using 
SuperSignal West Pico Chemiluminescent Substrate System (Pierce). Electrophoresis 
analysis of OCT4 and SOX2 was performed by Eugenie Cheng. All other electrophoresis 
experiments were performed by Robert Leone. 
 
Alkaline phosphatase analysis. Direct alkaline phosphatase (AP) activity was assessed 
using Alkaline Phosphatase Staining Kit (Stemgent, Inc, Cambridge, MA) according to 
the manufacturer’s recommendations. Alkaline phosphatase analysis was performed by 
Robert Leone.
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RESULTS 
mRNA and DNA transfection. Transfection experiments were performed on human 
neonatal keratinocytes and fibroblasts. Keratinocytes have been reported to reprogram to 
iPS cells with faster kinetics and greater efficiency than human fibroblasts (18, 44). In 
unpublished data from our lab (Peter Rabinovich), it was demonstrated using rt-PCR that 
GFP mRNA transcripts maintain a half-life of approximately 4-5 hours in human 
lymphocytes, leaving only 10% of material after 15 hours. Because transfected mRNA 
transcripts are transient in cells and because translated proteins are diluted two-fold with 
each cellular division, the kinetic advantage of keratinocytes in reprogramming was 
thought to be an important attribute of our system. mRNA transfection was attempted by 
both electroporation using the Amaxa Nucleofector II as well as the Mirus system of 
cationic liposome-mediated transfection. To determine optimal electroporation 
parameters using Amaxa Nucleofector II, we first transfected keratinocytes with a green 
fluorescent protein (GFP) reporter gene from Pontellina plumata, using mRNA and DNA 
transgenes. Using keratinocyte electroporation solution proprietary to Amaxa we tested 
several electroporation protocols and determined that Nucleofector II program T-024 
gave the highest efficiency of transfection when assessed by geometric mean (fig. 1).  
Transfection experiments using liposomal reagents on cells in fibroblast and 
keratinocytes in cultures were assessed by similar methods and attained similar 
efficiencies of transfection (data not shown). 
 
To assess the functionality of mRNA transcripts, transcripts for OCT4, SOX2, KLF4, c-
MYC, P53DD, and NANOG were individually transfected into neonatal human foreskin 
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fibroblasts. Protein synthesis was assessed by Western blot analysis as shown in figure 2. 
Upon transfection each transcript allowed for significant protein production compared 
with untransfected control fibroblasts. (Sample quantities were standardized by 
determining pre-lysis cell quantity or by protein quantitation of cell lysates by 
bicinchoninic acid (BCA) protein assay). In all cases protein synthesis was evident above 
levels of untransfected control samples. Western blot analysis for NANOG showed 
detectable protein in untransfected controls fibroblasts. This is in concordance with a 
recent report of low-level basal NANOG expression in human fibroblasts (53).  
 
Introduction of pluripotency factors into keratinocytes and fibroblasts.  
Introduction of reprogramming factors using mRNA retroviruses.  
For preliminary studies, retroviral transfection was performed to induce pluripotency in 
keratinocytes according to published methods (18, 52). Using a 1:1:1:1 mixture of 
retroviruses containing reprogramming factors (OCT4, SOX2, KLF4, c-MYC), 
keratinocytes (passage 5) were infected twice, 24 hours apart. Two days after the last 
infection, cells were trypsinized and seeded onto a feeder layer of irradiated mouse 
embryonic fibroblasts (iMEFs) in embryonic stem (ES) cell medium.  Expression of 
retrovirally inserted genes was assessed by fluorescent microscopy and flow cytometric 
analysis of GFP expression one day post transfection. (fig. 3a-c) The fraction of cells 
expressing reprogramming factor ranged from 15% to 78% among the four samples.  
Despite rather low expression rates, induction of pluripotency was evidenced by 
formation of three colonies displaying typical ES cell morphology, each of which was 
positive for alkaline phosphatase activity, an early marker of pluripotency (fig. 3d). 
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Introduction of reprogramming factors by mRNA transfection.  
Using optimized conditions, keratinocytes were transfected with mRNA transcripts 
coding for reprogramming transcription factors. Initially, keratinocytes were 
electroporated with OCT4, SOX2, KLF4, and c-MYC mRNA transcripts (day 0).  After 
transfection, cells were grown in keritinocyte medium for 2 days without a feeder cell 
layer. On day 2, cells were trypsinized and moved to iMEF feeder cell layers in multi-
well plates at a density of approximately 5000 cells/cm2. Medium was changed to ES cell 
medium on day 3 after transfection. Thereafter, cells were grown in ES cell medium with 
or without 10 mM valproic acid (VPA) supplement. Medium was changed every other 
day. Two control populations of keratinocytes were treated to the same culture 
conditions, again with and without VPA. Transfected keratinocytes began to show 
evidence of transformation on day 4, at which time small colonies began to form that 
were particularly abundant in VPA-containing cultures. The colonies were tightly packed 
and mostly circular with relatively smooth edges (fig. 4b,d), bearing significant 
morphologic similarity to both human embryonic stem cell colonies as well as virally 
induced iPS cell colonies (fig. 4a). There were approximately 10-15 colonies/cm2 in 
VPA-containing culture conditions and 6-10 colonies/cm2 in cultures without VPA, and 
the rate of growth of individual colonies appeared to be slightly higher in VPA-
containing conditions. However, the morphology of the colonies was not appreciably 
different between culture conditions (with or without VPA; fig. 4b,d).  No colonies were 
observed in control cell cultures (no mRNA transfection performed) in either the 
presence or absence of VPA (fig. 4c,e). Colonies were assessed for pluripotency by 
determining alkaline phosphatase activity at day 10 and day 14. Colonies failed to show 
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alkaline phosphatase activity in this initial experiment. Human fibroblasts were 
transfected using a similar protocol, but showed no evidence of colony growth in either 
VPA treated or untreated culture conditions (data not shown). It was observed that 
keratinocytes survived the above transfection relatively poorly, demonstrating a viability 
only of about 3 percent.  
 
We also attempted serial transfections of reprogramming factors into human 
keratinocytes using a liposomal delivery of mRNA transcripts.  Three transfections were 
carried out on days 0, 3, and 6 on keratinocytes cultured on irradiated mouse embryonic 
fibroblast feeder cells. While cellular transformation was again achieved in a manner 
similar to results reported for electroporation experiments described above, all colonies 
were alkaline phosphatase negative (data not shown).  Using GFP mRNA, it was 
discovered that keratinocytes were actually resistant to transfection of mRNA material 
after the initial transfection at day 0 (data not shown). 
 
In subsequent experiments several additional approaches were attempted to affect 
successful transformation to pluripotency. In published reports, addition of NANOG to 
OCT4, SOX2, KLF4, and c-MYC increased the efficiency and the kinetics of 
reprogramming in human and mouse fibroblasts. This has been shown in both retroviral 
as well as episomal systems of transformation (37, 50). Particularly interesting about this 
approach is that the addition of NANOG seems to increase the kinetics of reprogramming 
in a fashion that is relatively independent of cellular proliferation rates (50). This is 
especially applicable to our system since mRNA transcripts in our system, unlike mRNA 
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produced from retrovirally-integrated genes, are not being actively produced or 
replenished by the cell during reprogramming. Thus, in addition to the loss in 
cytoplasmic mRNA concentration due to normal cellular control mechanisms, transcripts 
are diluted by half with each population doubling. NANOG mRNA was synthesized in 
vitro as described for the other four factors. Using Western blot analysis, we confirmed 
expression of NANOG protein by a transfection experiment using nHFF cells (fig. 5). 
The immunoblot showed increased levels over untransfected nHFF cells, however the 
evidence of endogenous NANOG expression in control sample was unexpected and 
likely due to contamination or nonspecific staining. In an attempt to induce pluripotency, 
nHEK cells were transfected with OCT4, SOX2, KLF4, c-MYC, and NANOG in a 
1:1:1:1:1 ratio. In culture conditions without valproic acid (VPA), small colonies began 
to become evident on day 4 post-transfection. Two of these colonies showed steady 
growth over the first 11 days post transfection after which time their size stabilized. 
These colonies appeared smaller than colonies formed from the four factors alone, 
however they shared their general morphological attributes, being round with distinct 
borders.  (No colonies were evident in culture conditions containing 1 mM valproic acid.) 
Cells were stained for alkaline phosphatase activity. We observed two alkaline-
phosphatase positive cells that were round with smooth cell borders, distinct from both 
native keratinocyte morphology, as well as fibroblast morphology of the feeder layer 
cells (fig. 6).  Beyond these findings of individual cells, cell colonies in this sample 
showed no alkaline phosphatase activity. Approximately 9 x 104 cells were plated in one 
well of a 24-well plate to achieve these results. 
  
24 
 
In another approach, we took advantage of recent reports showing that the stoichiometry 
of the expression of the four factors plays a role in optimal cellular transformation to 
pluripotency (54). Specifically, Papapetrou et al. have shown that reprogramming human 
fibroblasts to iPS cells is highly sensitive to levels of OCT4 and is optimized when the 
four proteins are present intracellularly in a ratio of 3:1:1:1 (OCT4:SOX2:KLF4;c-
MYC).  Accordingly, we transfected nHEK cells with the mRNA of the four factors in 
precisely this ratio. In both VPA-positive and VPA-negative culture conditions, cellular 
transformation was noted, showing one large colony per well, and many small round 
colonies that began to appear at day 4 post-transfection. These were similar in appearance 
to those produced through four factor transfection pictured in figure 4. On day 16 post-
transfection, these colonies were stained for alkaline phosphatase activity as described. 
There was no significant alkaline phosphatase activity above negative control cells of 
untransfected nHEK. 
 
Lastly, there have been several reports of the increased efficiency of reprogramming in 
the setting of P53 knockdown through use of either shRNA or a P53 dominant negative. 
P53 activity was more completely inhibited using a P53 dominant negative construct 
consisting of the first 14 N-terminus codons plus the C-terminus 302-390 originally 
described by Shaulian et al. (55).  We synthesized this construct (P53DD) and confirmed 
expression by immunoblot analysis (fig. 5) with a primary antibody directed against the 
carboxy terminus of P53 (Pab421, Calbiochem). nHEK cells were transfected with 
OCT4, SOX2, KLF4, c-MYC, and P53DD in a 1:1:1:1:1 ratio. Very small colonies began 
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to appear on day 4 post-transfection.  In contrast to experiments using the four factors and 
either NANOG or high OCT4 levels, these colonies remained very small without 
noticeable growth. Staining for alkaline phosphatase was done and yielded no significant 
results above negative control cells.  There was no observable difference between VPA-
positive and VPA-negative culture conditions. 
 
Assessing keratinocyte viability in mRNA electroporation experiments. In carrying 
out the above experiments, it was observed that there was significant loss of cell viability 
after each mRNA transfection of keratinocytes. Cell loss ranged from 96-98% in 
experiments using all four factors, which used a total mRNA concentration of 120-150 
µg/ml.  This was significantly more than control keratinocytes that were electroporated 
without any mRNA in the transfection solution and which showed a more modest 60% 
loss in viability.  It had previously been reported that mRNA showed very little toxicity 
in the electroporation of various other human cell types, including lymphocytes, 
fibroblasts and monocytes (41, 43, 64). The experiments described in these reports used 
mRNA at levels approximately equal to those used in our experiments. Initially, it was 
unclear whether the significant toxicity observed in our experiments was secondary to 
high mRNA levels or to the effect of the expression of the reprogramming factors 
themselves. To investigate this further, we compared viability data from nHEK 
electroporation experiments using increasing concentrations of GFP mRNA, expression 
of which has been previously shown not to be toxic in human cells (41, 43).  We 
compared three groups of nHEK cells, including cells undergoing electroporation with no 
mRNA present, and two groups of cells electroporated with 30 µg/ml and 200µg/ml of 
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GFP mRNA respectively. Post-transfection all cells were incubated overnight in 
keratinocyte medium, after which they were trypsinized and anaylized for cell viability 
by manual counting with a hemocytometer (fig. 7). Data from this experiment show that 
increasing concentrations of GFP mRNA is toxic to human keratinocytes. 
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DISCUSSION 
The use of retrovirally introduced transcription factors has been exceptionally and 
reproducibly successful as a general approach to the induction of pluripotency in somatic 
cells. We are indebted to researchers using these methods in the inception and early 
development of the field iPS cell technology. Beginning with the revelatory work of 
Yamanaka, the use of retroviruses to introduce transformative factors has produced great 
advances in our understanding of the capacity for differentiated cells to adopt pluripotent 
states. Using these methods researchers have unlocked the ability of somatic cells to be 
transformed into many tissues of the body, including cardiomyocytes, hematopoietic stem 
cells, osteoclasts, hepatocytes, and neurons (18, 23, 24, 56, 57, 58, 59). Researchers have 
also been successful in correcting genetic mutations in iPS cells derived from patients or 
mouse models with genetic mutations causing Duchenne muscular dystrophy, 
hemophilia, and sickle cell anemia, and subsequently differentiated these cells into 
disease-free phenotypes (60, 61, 62, 63). Work has also been accomplished, using similar 
methods of viral transformation, in transdifferentiating between somatic cell types, such 
as transforming pancreatic exocrine cells into insulin-producing beta islet cells (64). 
Importantly, all of this work has been accomplished—much of it in human systems—
without the specter of ethical suspicion or political-legal regulation hindering advances. 
Indeed, the advances that have already been uncovered, along with the promise of things 
to come are truly historic and will likely have implications on many aspects of society. 
  
Holding at bay future promise from becoming accepted advances, however, are current 
limitations of the technology of virally induced genetic material that has, to this point, 
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brought the field so far in such a short time. Insertional mutagenesis, transgene 
reactivation, and oncogenic transformation are all serious pitfalls in any reprogramming 
technology using DNA as the transformative element, especially those employing 
retroviruses. The potential of using mRNA transfection technology to induce 
pluripotency is an important advance in removing these last hurdles before clinical 
application of iPS technology. 
 
In the current work we have accomplished important steps toward fulfillment of this goal.  
We have successfully synthesized mRNA constructs corresponding to the transformative 
factors OCT4, SOX2, KLF4, c-MYC, and NANOG and demonstrated their expression 
individually in human fibroblasts. We have also demonstrated that these factors can be 
used reproducibly to affect cellular transformation of human keratinocytes in culture.  
Lastly, although the efficiency was low, we have observed the presence of two alkaline-
phosphatase-positive cells through keratinocyte reprogramming with OCT4, SOX2, 
KLF4, c-MYC, and NANOG in the absence of valproic acid. It remains to be seen if 
these cells are capable of forming viable colonies. The pluripotent potential of cells 
transformed in this way will be investigated in future work. Evaluation of expression of 
other markers of pluripotency markers such as SSEA-4, SSEA3, TRA-1-60, TRA-1-81 
will be very important, as well as assessing the potential of these cells to form teratomas 
or differentiate into other somatic cell types by known methods. 
 
We believe the most significant advantage of our approach—the transient nature of 
intracellular mRNA—is also its most challenging limitation. Previous experiments 
  
29 
showed GFP protein expression up to 2 weeks post-electroporation in human cells 
(unpublished data, Peter Rabinovich). However, in our examination of protein expression 
of OCT4 and SOX2 in mRNA-transfected human fibroblasts, transgene proteins were 
expressed for less than 6 days post-transfection (data not shown). Previous studies 
investigating the kinetics of reprogramming have found that at least 7 days of transgene 
expression is necessary for pluripotent transformation. We have attempted to address this 
issue by using approaches that have been reported to increase the kinetics of 
reprogramming, including the use of the four standard factors plus either NANOG or 
knockdown of P53 activity. (Our choice of keratinocytes as starting cells, which have 
been reported to have faster reprogramming kinetics, was also made with this in mind). 
Though it appears that the use of four factors plus NANOG has improved the 
reprogramming process (as evidenced by the generation alkaline-phosphatase positive 
cells), the efficiency of the process must be further optimized. This limitation may be 
further addressed in one of several ways. One approach would be to increase the half-life 
of mRNA in cells. It is possible that this could be achieved using constructs from 
negative RNA viruses, such as the Sendai virus, which enable the replication of mRNA 
strands in mammalian cytosol. Our lab is presently investigating the viability of this 
approach in several systems. Another approach would be to investigate the viability of 
repeated transfections of reprogramming factors performed in the course of cellular 
transformation. A similar approach was successfully implemented by Zhou et al. who 
achieved pluripotent transformation using recombinant protein reprogramming factors 
(65). In the present study we attempted serial transfections using a cationic-liposomal 
method. Using this approach, which allows for in situ transfection of cells in culture, we 
found that keratinocytes were unable to be transfected once they were exposed to ES 
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culture conditions (data not shown). While the reason behind this recalcitrance is unclear, 
it may be possible that optimization of transfection medium during reprogramming could 
produce a more favorable environment for transfection (66).  While multiple 
electroporations of keratinocytes was an untenable idea in our present system considering 
the extremely low cell viability using the Amaxa Nucleofector II, there are other 
approaches to electroporation which may allow the possibility of multiple in situ 
transfections of these adherent cells (67, 68). 
 
An unexpected finding in our study was that of the apparent toxicity of high levels of 
mRNA on keratinocytes during electroporation. The implications of this finding are 
unclear at present. Several previous reports, including work done in our lab, had 
uncovered no toxic effect of similar levels of mRNA (GFP) on mammalian cells, 
including human fibroblasts, lymphocytes, peripheral blood mononuclear cells, and 
murine splenocytes (41, 43, 69). In these studies, the subsequent expression of GFP 
protein was also not found to be toxic to these cells. This led us to speculate that it was 
the increasing concentration of mRNA itself that was toxic to keratinocytes. It is known 
that keratinocytes are subject to a phenomenon known as the “ribotoxic stress response.” 
This response involves the activation of stress-activated protein kinases (SAPK) and is 
typically triggered by damage to ribosomal RNA by toxins, antibiotics, UVB radiation, or 
other cellular stressors. Interestingly, the SAPK cascade, which often results in cellular 
apoptosis, can only be triggered by ribosomes that are actively translating (70, 71, 72). It 
is possible that such a mechanism, wherein cell death is correlated to the intensity of 
protein synthesis, may be involved in the results we have observed. That is, as a higher 
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concentration of mRNA is introduced into cells and translational machinery is more fully 
engaged, all during the stress of electroporation and concomitant recovery, cells become 
more highly susceptible to the mechanisms of ribotoxic stress response. Future 
investigations should be made into the benefit of delaying protein translation for some 
amount of time after electroporation.  This could be accomplished by the use of a 
reversible inhibitor of protein biosynthesis such as cyclohexamide. If keratinocyte cell 
death is in fact related to the degree of ribosomal activity, a delay of such activity until 
after cellular recuperation might lessen the effect.  Whatever the mechanism of cell death, 
it is clear that the electroporation process is selecting for a rather small subpopulation of 
keratinocytes. Whether these surviving cells are more or less likely to be reprogrammed 
is not known. The fact that they have demonstrated morphological transformation and 
some evidence of alkaline-phosphatase activity is quite encouraging, however. In the 
future, the issue of poor cell viability may be addressed by decreasing mRNA 
concentration in electroporation experiments, as well as investigating alternative 
transfection procedures. Using keratinocytes at lower passage number may also increase 
the health and subsequent viability of these cells. 
 
Future work on this project will be directed in several directions. First, effort will be 
directed towards more fully elucidating the nature of the transformed cell colonies that 
have been produced from the reprogramming of keratinocytes in this work.  Because of 
the poor cell viability after electroporation with mRNA, we did not have sufficient cells 
from experiments that produced alkaline-phosphatase activity to apply more stringent 
pluripotency assays.  This will be of foremost importance in future work.  The important 
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question is whether these cells (as well as cells that have been morphologically 
transformed and do not show alkaline phosphatase activity) show any further 
characteristics of pluripotency.  This can be done by comparing molecular markers such 
as epigenetic patterns of CpG methylation and histone acetylation on promoter regions of 
key pluripotency genes such as OCT4 and NANOG. Microarray data could also be 
obtained and compared between transformed cells, iPS cells, ES cells, and known 
malignant phenotypes of keratinocytes. RT-PCR experiments would also be valuable in 
determining precise levels of transcripts that are known to be associated with 
pluripotency (SSEA-4, SSEA3, TRA-1-60, TRA-1-81), as well as levels of transcripts 
that specifically indicate a differentiated keratinocyte phenotype. Second, increasing the 
half-life of mRNA in cells will be an important step towards more effective 
reprogramming. This work is presently being engaged in our lab with emphasis on 
uncovering proteins or nanoparticles which have the ability to stabilize ectopic mRNA.  
As mentioned above, strategies that allow for repeated in situ transfections would be 
useful in prolonging the presence of mRNA and expressed protein factors in cells.  Third, 
there will be continued effort directed toward improving the kinetics of reprogramming in 
our system. Possible approaches include using additional transformative factors such as 
Lin28, which has been shown to increase rate and efficiency of iPS cell formation (44). 
Lastly, using alternative starting cell populations may also allow faster and more efficient 
reprogramming. A recent study by Eminli et al. et al showed that less differentiated cells 
of the hematopoietic system are more amenable to reprogramming than mature cells (45).  
A trial using CD34+ cells as a starting population, for instance, would be an interesting 
experiment. In our experience, keratinocytes appear to be unusual in their sensitivity to 
high mRNA concentrations during electroporation. As such, we believe that cell types 
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other than keratinocytes will likely not encounter similar problems with post-
electroporation viability. 
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Figure 1. Flow cytometry analysis of keratinocyte (nHEK) transfection reactions 
using three Amaxa Nucleofector II programs. (A) Untransfected control keratinocytes 
show essentially no fluorescence. (B) Electroporation of keratinocytes with GFP mRNA 
compared with GFP DNA plasmid with fraction of GFP-expressing cells shown; 
GM=Geometric Mean; nHEK=neonatal Human Epidermal Keratinocytes; GFP=Green 
Fluorescent Protein.. 
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Figure 2. Immunoblots of neonatal human foreskin fibroblasts (nHFF) transfected 
with mRNA as shown. (A) First lane: untransfected nHFF; second lane: nHFF 
transfected with OCT4 mRNA transcripts. (B) First lane: untransfected nHFF; second 
lane: nHFF transfected with SOX2 mRNA transcripts. (A) First lane: untransfected 
nHFF; second lane: nHFF transfected with KLF4 mRNA transcripts. (A) First lane: 
untransfected nHFF; second lane: Jurkat cells as positive control; third lane: nHFF 
transfected with c-MYC mRNA transcripts. Samples were standardized either by cell 
counts (A-C) or direct protein quantitation (75 µg in each lane of gel pictured in D). 
A B C D 
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Figure 3.  Neonatal human epidermal keratinocyes (nHEK) infected with four 
retroviruses containing reprogramming factors OCT4, SOX2, KLF4, and c-MYC. 
(A) Flow cytometry data for nHEK cells individually infected with retroviruses 
containing one of the four reprogramming factors. (B) Infected nHEK cells infected with 
all four reprogramming factors, three days post-infection at 100x magnification; (C) 
nHEK cells from (B) under UV microscopy and displaying production of GFP marker, 
confirming transgene expression; (D) Representative colony stained by alkaline 
phosphatase assay. nHEK=neonatal Human Epidermal Keratinocytes. 
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Figure 4. Representative morphology of transformed cell colonies 7 days post-
transfection. (A) Representative colonies of human embryonic stem cells (hES H1 P60) 
grown on iMEF feeder layer pictured here for morphologic comparison; (B) 
Representative colony of transformed nHEK cells at day 7 post-transfection with no VPA 
exposure; (C) Control well seeded with untransfected nHEK cells and exposed to the 
same culture conditions (no VPA) as cells in (B); (D) (B) Representative colony of 
transformed nHEK cells at day 7 post-transfection with 3 days of VPA exposure; (E) 
Control well seeded with untransfected nHEK cells and exposed to the same culture 
conditions (3 days in VPA) as cells in (D). 
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Figure 5. Immunoblot analyses of neonatal human foreskin fibroblasts (nHFF) 
transfected with mRNA as shown. (A) First lane: untransfected nHFF; second lane: 
nHFF transfected with NANOG mRNA transcripts. (B) First lane: untransfected nHFF; 
second lane: nHFF transfected with P53DD mRNA transcripts.  
 
A B 
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Figure 6. Alkaline phosphatase activity of human embryonic stem cells and 
transfected human keratinocytes (A) Representative colonies of human embryonic 
stem cells (hES H1 P60) grown on matrigel and stained for alkaline phosphatase activity; 
(B-C) Two small round cells produced from electroporation of five transcription factors 
(OCT4, SOX2, KLF4, c-MYC, and NANOG) into neonatal human epidermal 
keratinocytes demonstrating alkaline phosphatase activity at day 16 post transfection. 
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Condition Cell survival at 18 hours 
Electroporation: no mRNA 6.4 x 104 cells 96 
Electroporation: 30 µg/ml GFP mRNA 5.3 x 104 cells 109 
Electroporation: 300 µg/ml GFP mRNA 6.2 x 103 cells 5 
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Figure 7. Keratinocyte viability after electroporation with increasing concentrations 
of GFP mRNA.  (A) Cell counts 18 hours post-transfection show decreasing viability 
relative to increasing mRNA concentration used in transfection. Starting amount was 
approximately 2 x106 cells in each transfection. (B) Flow cytometry data showing 
showing increasing mean fluorescence with increasing mRNA concentration. A low-
fluorescing population of cells make up a more significant percentage of cell population 
in the high-concentration mRNA transfection sample. nHEK=neonatal Human Epidermal 
Keratinocytes.
nHEK + electroporation, no mRNA 
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